



Latest Insights on Evidence-based Dietary Approaches for Cholesterol Reduction



Corrine Toyn, Healthcare Professional Relations Manager, Benecol Ltd.

Cardiovascular disease (CVD) is the collective umbrella term that encompasses all disease states affecting the heart or blood vessels, with coronary artery disease being the most prevalent. CVD is the primary cause of death worldwide,¹ and in the UK, more than 10% of the population are living with CVD, with a quarter of all deaths attributable.²

The landmark longitudinal Framingham Heart Study – which was established in 1948 – enabled identification of risk factors for CVD, divided into non-modifiable (e.g. age, family history and ethnicity) and modifiable factors (e.g., hypercholesterolemia, hypertension, physical inactivity, obesity, diabetes mellitus and alcohol intake).³

Cholesterol is a waxy fat-like substance derived from two sources – exogenous dietary cholesterol and endogenous de novo synthesised cholesterol. While cholesterol plays a fundamental role in the maintenance of membrane permeability and fluidity, as well as synthesis of steroid hormones, bile acids and vitamin D, it is well established that an increase in total blood cholesterol concentrations above the normal range (<5 mmol/L) significantly increases risk of CVD.⁴

Lipids are insoluble in water; thus, lipoproteins serve as vehicles for transportation of cholesterol (in addition to triglycerides and other fat-soluble components) in the circulation. Low density lipoproteins (LDL) transport

cholesterol to peripheral tissues, whereas high density lipoproteins (HDL) are responsible for the reverse cholesterol transport from peripheral tissues. If blood LDL-cholesterol (LDL-C) is elevated, cholesterol can deposit in the arterial lumen leading to plaque formation and narrowing of the blood vessels – the hallmark feature of atherosclerosis. Research has also demonstrated that sub-clinical atherosclerosis is frequent even in those individuals with LDL-C levels within the target range (<3 mmol/L).⁵⁻⁷

In view of the plethora of evidence demonstrating clinical efficacy and safety, a high-intensity statin, defined as the dose at which a reduction in LDL-cholesterol of >40% is achieved, is considered first line treatment for LDL-C lowering.⁸ Notwithstanding the unquestionable benefits, there remains limitations with statins including possible mild side effects such as musculoskeletal symptoms and potentially higher risk of certain health conditions such as haemorrhagic stroke.⁹

“The emergence of different dietary approaches with a plant-based ethos are not only important for cardiovascular health but also planetary health.”

A key influencing factor on blood cholesterol levels is dietary saturated fat intake, thus potentially increasing risk of CVD.¹⁰ This article will explore the latest insights on evidence-based dietary approaches for blood cholesterol reduction.

Evidence based dietary approaches for CVD risk reduction

The emergence of different dietary approaches with a plant-based ethos are not only important for cardiovascular health but also planetary health.¹¹⁻¹⁵ In the UK, there has been a seismic shift in the number of people adopting meat-free or meat-reduced diets. Approximately a quarter of the population follow some form of plant-based eating; 1-2% vegan, 5-10% vegetarian, 15-20% flexitarian.¹⁶ Some plant-based dietary approaches have similarities regarding what they recommend and have been associated with CVD prevention and/or reduced risk of CVD events (**Table 1**).

An important dietary component to consider in the context of cholesterol, a risk factor of coronary heart disease, are plant stanols. Plant stanols are naturally occurring compounds found in small amounts in plant-based foods (e.g.,

wholegrains, vegetable oils, nuts, seeds, fruit, vegetables). These amounts from food alone do not result in clinically meaningful outcomes on blood cholesterol and subsequent CVD prevention and/or reduced risk. Hence, there is emphasis on the importance of incorporating foods with added plant stanols (e.g., spreads, yogurts, yogurt drinks).

Overview of plant stanols and reduction of LDL-cholesterol

Plant stanols are structurally similar to cholesterol. It has been suggested they decrease plasma cholesterol concentration by:

1. Reducing small intestinal absorption of cholesterol (plant stanols interfere with the solubilisation of cholesterol i.e., the incorporation of cholesterol into mixed micelles).
2. Upregulating hepatic expression of the LDL receptors.
3. Decreasing production of endogenous LDL-cholesterol.^{34, 35}

Emerging evidence suggests that plant stanols may have additional health benefits, that have to date been largely unnoticed, including interactions with the innate and adaptive immune system.³⁶

Table 1: Overview of Dietary Approaches for the Management of Risk Factors for Cardiovascular Health

Dietary approach	Explanation	Research
DASH* Diet <small>*Dietary Approaches to Stop Hypertension</small>	Limits sodium to 2,300 mg/d (1 tsp salt). Focuses on foods rich in potassium/magnesium/calcium. Limits red meat, sugars, and saturated fat.	Improvements in cardiovascular risk factors. ¹⁷ Protective against CVD, CHD, stroke, and heart failure risk. ¹⁸ Significant reductions in total cholesterol and LDL-C. ¹⁹ Modest adherence associated with lower risk of all-cause/cause-specific mortality. ²⁰ Higher adherence confers reduced risk of coronary artery disease. ²¹
Mediterranean Diet	Varies by country/region. Inspired by the eating habits of people who live near the Mediterranean Sea (e.g., Greece, Spain etc.).	Protective effect on risk of CVD, including CHD and ischemic stroke. ²² Beneficial role on CVD prevention ²³ and associated with lower risk of CVD incidence/mortality. ²⁴ Improved survival in people with history of CVD. ²⁵
Flexitarian Diet	The flexitarian dietary approach is plant-based incorporating some animal/fish protein.	Lower CVD-related risk factors (e.g., LDL-C). Observational studies support their role in prevention of CVD. ^{26, 27} Associated with decreased total cholesterol, LDL-C, HDL-C. ²⁸
Nordic Diet	A modern style of eating based around traditional Scandinavian cuisines. Focus is on sustainable, local, seasonal foods.	Improvements in blood pressure/some blood lipid markers. ²⁹ Inverse association with risk of mortality. ³⁰ Adherence to diet and cardiometabolic risk factors are equivocal. ³¹
Portfolio Diet	A dietary approach to specifically lower cholesterol. Based on eating a 'portfolio' of foods shown to help lower cholesterol.	Significant improvements in LDL-C, cardiometabolic risk factors and estimated 10-year CHD risk. ³² High adherence associated with reduction in cardiovascular events. ³³

Achieving the recommended amounts of plant stanols in the diet is unobtainable. In fact, a typical Westernised diet contains a very small amount of plant stanols (20-30 mg/d). In contrast, foods with added plant stanols (aiming for approximately 2 g/day with meals) are clinically effective in lowering LDL levels by an average of 10% in two-to-three weeks. Furthermore, a daily intake of plant stanols reduces serum total cholesterol and LDL-C dose dependently from 7-12.5% on average, with no effect on HDL cholesterol.³⁷⁻⁴⁰

Cholesterol reduction can be sustained with daily intake however plant stanol ester must be consumed daily to gain long term benefits.⁴¹ This effect is in addition to that obtained with a low-fat diet or use of statins.⁴² Thus, consuming foods with added plant stanols is an important consideration for certain patient groups who require appropriate dietary intervention to reduce risk of CVD-related events. The European Society of Cardiology (ESC) recommendations for the patient groups in which food with added plant stanols (aiming for

approximately 2 g/day with meals) may be considered include:⁴²

- Patients at intermediate risk of CVD who are not on statins.
- Patients on statins who do not reach their LDL targets.
- Patients with familial hypercholesterolemia.

The LDL-lowering effect of plant stanols has been summarised in several reviews and meta-analyses of randomised controlled trials and is considered one of the most established cholesterol-lowering functional food ingredients globally.⁴³⁻⁴⁷

In clinical practice, it is also important to consider plant stanol use for other at-risk groups (e.g., menopausal women, overweight/obesity, family history of CVD, diabetes) that could benefit from cholesterol lowering interventions.

Conclusion

Dietary approaches are the cornerstone of strategies to lower blood cholesterol levels. A complementary plant-based diet approach that focuses on CVD prevention and/or reduced risk is fundamental. A flexitarian approach that encourages plant-based

meals, but that doesn't necessarily exclude all animal products is likely to be achievable for many patients.⁴⁸ Given that the amount of plant stanols required to achieve a clinically meaningful cholesterol lowering effect is unobtainable through diet alone, there remains strong emphasis on the incorporation of foods with added plant stanols (aiming for approximately 2 g/day).

Clinical practice takeaways

- There is strong clinical evidence that plant-based dietary approaches can be used to reduce LDL-C.
- Encouraging use of foods with added plant stanols for certain patient groups, as outlined in ESC (2021) guidelines is recommended, alongside a complementary patient-centred plant-based dietary approach focusing on CVD prevention.
- Foods with added plant stanols are effective in lowering LDL levels by an average of 10% with consumption of 2 g plant stanols/day, with no effect on HDL cholesterol. This can be achieved in two-to-three weeks. The effect is sustained with sufficient daily consumption – with main meals.

References: 1. World Health Organization (WHO) (2021). Cardiovascular diseases (CVDs). Accessed online: www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-cvds (Feb 2022). 2. Ahmad S, Kassianides X, Thackray S. (2021). Cardiovascular disease: the state of the nation, and the NHS Long Term Plan. *Br J Cardiol*; 28(2): S3-S6. 3. Andersson C, et al. (2019). 70-year legacy of the Framingham Heart Study. *Nat Rev Cardiol*; 16: 687-698. 4. Afonso MS, et al. (2018). Molecular Pathways Underlying Cholesterol Homeostasis. *Nutrients*; 10(6): 760. 5. Raposeiras-Roubin S, et al. (2021). Triglycerides and residual atherosclerotic risk. *J Am Coll Cardiol*; 77(24): 3031-3041. 6. Fernández-Friera L, et al. (2017). Normal LDL-cholesterol levels are associated with subclinical atherosclerosis in the absence of risk factors. *J Am Coll Cardiol*; 70: 2979-2991. 7. Won KB, et al. (2019). Independent role of low-density lipoprotein cholesterol in subclinical coronary atherosclerosis in the absence of traditional cardiovascular risk factors. *Eur Heart J. Cardiovascular Imaging*; 20: 866-872. 8. National Institute for Health and Care Excellence (NICE) (2014). Cardiovascular disease risk assessment and prevention. Accessed online: <https://bnf.nice.org.uk/treatment-summary/cardiovascular-disease-risk-assessment-and-prevention.html> (Feb 2022). 9. Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. (2018). Statins: pros and cons. *Med Clin (Barc)*; 150(10): 398-402. 10. Soliman GA (2018). Dietary Cholesterol and the Lack of Evidence in Cardiovascular Disease. *Nutrients*; 10(6): 780. 11. Choi Y, et al. (2021). Plant-Centered Diet and Risk of Incident Cardiovascular Disease During Young to Middle Adulthood. *J Am Heart Assoc*; 10(16): e020718. 12. Kim H, et al. (2019). Plant-Based Diets Are Associated With a Lower Risk of Incident Cardiovascular Disease, Cardiovascular Disease Mortality, and All-Cause Mortality in a General Population of Middle-Aged Adults. *J Am Heart Assoc*; 8(16): e012865. 13. Crimmaro A, et al. (2020). A randomized crossover trial on the effect of plant-based compared with animal-based meat on trimethylamine-N-oxide and cardiovascular disease risk factors in generally healthy adults: Study With Appetizing Plantfood—Meat Eating Alternative Trial (SWAP-MEAT). *Am J Clin Nutr*; 112(5): 1188-1199. 14. Kahleova H, Levin S, Barnard ND. (2018). Vegetarian Dietary Patterns and Cardiovascular Disease. *Prog Cardiovasc Dis*; 61(1): 54-61. 15. British Dietetic Association (BDA) (2020). Eating patterns for health and environmental sustainability. Accessed online: www.bda.uk.com/uploads/assets/539e2268-7991-4d24-b9ee867c1b2808fc/a1283104-a0dd-476b-bda723452ae93870/one%20blue%20dot%20reference%20guide.pdf (Feb 2022). 16. Sajeev EPM, et al. (2020). Is the UK ready for plant-based diets? Report produced for the Global Food Security Programme. Accessed online: www.foodsecurity.ac.uk/publications (Feb 2022). 17. Siervo M, et al. (2014). Effects of the Dietary Approach to Stop Hypertension (DASH) diet on cardiovascular risk factors: a systematic review and meta-analysis. *Br J Nutr*; 113(1): 1-15. 18. Salehi-Abargouei A, et al. (2013). Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases-incidence: A systematic review and meta-analysis on observational prospective studies. *Nutrition*; 29(4): 611-618. 19. Lari A, et al. (2021). The effects of the Dietary Approaches to Stop Hypertension (DASH) diet on metabolic risk factors in patients with chronic disease: A systematic review and meta-analysis of randomized controlled trials. *Nutr Metab Cardiovasc Dis*; 31(10): 2766-2778. 20. Soltani S, et al. (2020). Adherence to the dietary approaches to stop hypertension (DASH) diet in relation to all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. *Nutr J*; 19(1): 37. 21. Yang Z, Yang Z, Duan M. (2019). Dietary approach to stop hypertension diet and risk of coronary artery disease: a meta-analysis of prospective cohort studies. *Int J Food Sci Nutr*; 70(6): 668-674. 22. Rosato V, et al. (2019). Mediterranean diet and cardiovascular disease: a systematic review and meta-analysis of observational studies. *Eur J Nutr*; 58: 173-191. 23. Becerra-Tomas N, et al. (2020). Mediterranean diet, cardiovascular disease and mortality in diabetes: A systematic review and meta-analysis of prospective cohort studies and randomized clinical trials. *Crit Rev Food Sci Nutr*; 60(7): 1207-1227. 24. Grosso G, et al. (2017). A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: Are individual components equal? *Crit Rev Food Sci Nutr*; 57(15): 3218-3232. 25. Tang C, et al. (2021). Mediterranean Diet and Mortality in People with Cardiovascular Disease: A Meta-Analysis of Prospective Cohort Studies. *Nutrients*; 13(8): 2623. 26. Gan ZH, et al. (2021). Association between Plant-Based Dietary Patterns and Risk of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. *Nutrients*; 13(11): 27. Trautwein EA, McKay S (2021). The Role of Specific Components of a Plant-Based Diet in Management of Dyslipidemia and the Impact on Cardiovascular Risk. *Nutrients*; 12(9): 28. Yokoyama Y, Levin SM, Barnard ND. (2017). Association between plant-based diets and plasma lipids: a systematic review and meta-analysis. *Nutr Rev*; 75(9): 683-698. 29. Ramezani-Jolfaei N, Mohammadi M, Salehi-Abargouei A. (2018). The effect of healthy Nordic diet on cardio-metabolic markers: a systematic review and meta-analysis of randomized controlled clinical trials. *Eur J Nutr*; 58: 2159-2174. 30. Jalilipour J, et al. (2020). The Nordic diet and the risk of non-communicable chronic disease and mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. *Crit Rev Food Sci Nutr*; 23: 1-13. 31. Kanerva N, et al. (2014). Associations of the Baltic Sea diet with cardiometabolic risk factors - a meta-analysis of three Finnish studies. *Br J Nutr*; 112(4): 616-626. 32. Chiavaroli L, et al. (2018). Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials. *Prog Cardiovasc Dis*; 61(1): 43-53. 33. Glenn AJ, et al. (2021). Relationship Between a Plant-Based Dietary Portfolio and Risk of Cardiovascular Disease: Findings From the Women's Health Initiative Prospective Cohort Study. *J Am Heart Assoc*; 10(16): e021515. 34. Gylling H, et al. (2014). Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. *Atherosclerosis*; 232(2): 346-360. 35. De Jong A, Plat J, Mensink RP. (2003). Metabolic effects of plant sterols and stanols (Review). *J Nutr Biochem*; 14(7): 362-369. 36. Plat J, et al. (2019). Plant-based sterols and stanols in health & disease: "Consequences of human development in a plant-based environment?" *Prog Lipid Res*; 74: 87-102. 37. European Food Safety Authority (EFSA) (2008). Plant stanol esters and blood cholesterol - Scientific substantiation of a health claim related to plant stanol esters and lower/reduced blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006 - Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies. *EFSA Journal*; 6(10): 825, 1-13. Accessed online: <https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2008.825> (Feb 2022). 38. European Food Safety Authority (EFSA) (2012). Scientific Opinion on the substantiation of a health claim related to 3 g/day plant stanols as plant stanol esters and lowering blood LDL-cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006. *EFSA Journal*; 10(5): 2692. Accessed online: <https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2012.2692> (Feb 2022). 39. European Food Safety Authority (EFSA) (2012). Scientific Opinion on the substantiation of a health claim related to 3 g/day plant stanols as plant stanol esters and lowering blood LDL-cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006. *EFSA Journal*; 10(5): 2693. Accessed online: <https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2012.2693> (Feb 2022). 40. Musa-Veloso K, et al. (2011). A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: Results of a meta-analysis of randomized, placebo-controlled trials. *Prostaglandins Leukot Essent Fatty Acids*; 85: 9-28. 41. Miettinen TA, et al. (1995). Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. *N Engl J Med*; 333(20): 1308-1312. 42. Visseren FLJ, et al. (2021). 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). *Eur Heart J*; 42(34): 3227-3337. 43. Jones P, et al. (2018). Progress and perspectives in plant stanol and plant stanol research. *Nutr Rev*; 76(10): 725-746. 44. Poli A, et al. (2021). Phytosterols, Cholesterol Control, and Cardiovascular Disease. *Nutrients*; 13(8): 45. Ras RT, Geleijnse JM, Trautwein EA. (2014). LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. *Br J Nutr*; 112(2): 214-219. 46. Talari R, et al. (2010). The Comparative Efficacy of Plant Sterols and Stanols on Serum Lipids: A Systematic Review and Meta-Analysis. *J Am Diet Assoc*; 110(5): 719-726. 47. Ying J, Zhang Y, Yu K. (2019). Phytosterol compositions of enriched products influence their cholesterol-lowering efficacy: a meta-analysis of randomized controlled trials. *Eur J Clin Nutr*; 73: 1579-1593. 48. Paivarinta E, et al. (2020). Replacing Animal-Based Proteins with Plant-Based Proteins Changes the Composition of a Whole Nordic Diet-A Randomised Clinical Trial in Healthy Finnish Adults. *Nutrients*; 12(4).



Sponsored content: This article has been commissioned and placed by Benecol. CN had no input into the content or reviewing of this article. This article is intended for healthcare professionals only.